Overview
Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring neuropeptide consisting of nine amino acids (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from rabbit brain venous blood in 1977 by Schoenenberger and Monnier. The peptide was identified through its ability to induce delta wave sleep (slow-wave sleep) in rabbits when administered intravenously, leading to its characteristic name.
Since its discovery, DSIP has been found to have far broader biological activity than initially recognized. Beyond sleep modulation, research has identified roles in stress adaptation, pain threshold elevation, circadian rhythm normalization, and modulation of the hypothalamic-pituitary-adrenal (HPA) axis. DSIP-like immunoreactivity has been detected throughout the human brain, pituitary gland, adrenal glands, and gastrointestinal tract.
Despite nearly five decades of research, DSIP remains an enigmatic peptide. Its receptor has not been definitively identified, its precise mechanism of sleep induction is unclear, and clinical trial data is limited primarily to European studies from the 1980s–2000s. The peptide's instability in plasma (half-life of minutes) and the difficulty of consistent synthesis have been significant obstacles to clinical development.
This guide examines the available research on DSIP, its proposed mechanisms, the limited clinical evidence, and practical considerations for those evaluating this peptide.
Quick facts
- Mechanism
- Neuropeptide modulating sleep architecture and stress response
- Primary use
- Sleep Regulation & Stress Adaptation
- Evidence
- limited
- FDA
- Not approved
- Route
- Intravenous or intranasal administration
- Typical results
- Improved sleep onset and quality reported within 1–2 weeks in limited studies
Chemical information
DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, a molecular mass of 848.8 g/mol, and the formula C₃₅H₄₈N₁₀O₁₅. Its amphiphilic character allows it to cross the blood-brain barrier. DSIP is notably unstable in plasma due to rapid aminopeptidase degradation, which has historically complicated its therapeutic development.
How DSIP works
DSIP's mechanism of action remains incompletely understood, which is unusual for a peptide that has been studied for nearly 50 years. No specific DSIP receptor has been definitively cloned, suggesting it may act through multiple receptor systems or through modulation of existing neurotransmitter pathways rather than a single dedicated receptor.
The most consistent finding is DSIP's ability to modulate sleep architecture by increasing delta (slow-wave) sleep without significantly altering total sleep time. This effect appears to involve GABAergic, serotonergic, and glutamatergic neurotransmission. DSIP may enhance the sensitivity of GABA-A receptors or modulate the release of sleep-promoting substances like adenosine and prostaglandin D2.
DSIP also demonstrates significant effects on the stress response. It has been shown to reduce cortisol and ACTH levels, modulate CRH (corticotropin-releasing hormone) signaling, and normalize circadian patterns of cortisol secretion in stressed individuals. These neuroendocrine effects suggest that DSIP functions as an endogenous stress-buffering peptide.
Additionally, DSIP has shown analgesic properties in both animal and limited human studies, potentially through modulation of endogenous opioid systems. It has been found to increase Met-enkephalin levels and may interact with delta-opioid receptor pathways, though this requires further confirmation.
- Delta wave promotion: Enhances slow-wave sleep through GABAergic and serotonergic modulation
- HPA axis normalization: Reduces cortisol/ACTH in stress states; normalizes circadian cortisol rhythm
- Circadian entrainment: May improve sleep-wake cycle regularity independent of sedation
- Opioid system modulation: Increases Met-enkephalin; potential analgesic effects
- Antioxidant effects: Demonstrated free radical scavenging and lipid peroxidation reduction
- Temperature regulation: Modulates hypothalamic thermoregulatory centers
Pharmacokinetics
Pharmacokinetic data is limited and primarily from early studies.
| Parameter | Value | Significance |
|---|---|---|
| Bioavailability (IV) | 100% | Direct systemic delivery |
| Bioavailability (Intranasal) | Estimated 10–30% | Lower but non-invasive route |
| Half-life | ~7–8 minutes (plasma) | Very short; rapid degradation by aminopeptidases |
| BBB penetration | Yes (amphiphilic) | Can reach central targets despite short half-life |
| Distribution | CNS, pituitary, adrenal, GI tract | Wide neuroendocrine distribution |
| Metabolism | Aminopeptidase degradation | Stabilized analogs may improve duration |
Dosing & administration
Clinical studies have used DSIP at doses of 25–30 nmol/kg (approximately 25 mcg/kg) administered intravenously, typically given 30–60 minutes before intended sleep onset. For a 75 kg adult, this translates to approximately 1.5–2.0 mg per dose.
Intranasal administration has been explored at higher doses (100–200 mcg) to compensate for lower bioavailability. Some practitioners report using subcutaneous injection at 100–300 mcg before bedtime, though this route has minimal clinical trial support.
Treatment protocols in published studies typically involved daily administration for 3–7 consecutive days, sometimes followed by a rest period. The optimal duration and dosing schedule remain poorly defined due to limited clinical data.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
DSIP has shown no significant toxicity in published studies, though the total body of human clinical data is limited. Early studies in chronic insomnia patients reported improvements in sleep quality without next-day hangover effects commonly seen with sedative-hypnotics. However, the absence of large-scale safety trials means the long-term risk profile is unknown.
Common
- • Mild drowsiness (expected therapeutic effect)
- • Transient dizziness
- • Mild headache
- • Occasional nausea
- • Injection site discomfort (IV/SC routes)
- • Vivid dreams (reported anecdotally)
Serious / potential risks
- • Very limited safety data from controlled trials
- • Unknown long-term effects
- • Theoretical excessive sedation at high doses
- • Unknown interactions with CNS depressants
- • Potential immunomodulatory effects with chronic use
Drug interactions
Drug interaction data is extrapolated from pharmacological mechanism; formal interaction studies have not been conducted.
| Medication | Interaction | Recommendation |
|---|---|---|
| Benzodiazepines / Z-drugs | Additive sedative/sleep-promoting effects | Use with caution; reduce sedative dose if combining |
| Opioid analgesics | DSIP modulates opioid pathways; additive sedation | Avoid combination; respiratory depression risk |
| Alcohol | Additive CNS depression | Avoid concurrent use |
| Corticosteroids | DSIP suppresses HPA axis; opposing effects | May reduce DSIP efficacy for sleep; monitor |
| Melatonin | Both modulate sleep architecture; potentially synergistic | May be used together; start with low doses of each |
Storage & handling
Lyophilized Powder
- • Store at -20°C for long-term stability
- • Protect from light and moisture
- • Reconstitute with bacteriostatic water immediately before use
- • Peptide is unstable in solution; minimize storage time
Reconstituted Solution
- • Use within 24–48 hours of reconstitution
- • Store at 2–8°C if not used immediately
- • Do not freeze reconstituted solution
- • Discard if discolored or contains particulates
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research peptide suppliers | $30–$80 per 5mg vial | Quality and purity vary; third-party testing essential |
| Compounding pharmacies | $100–$200 per month | Limited availability; prescription may be required |
| Intranasal preparations | $50–$150 per month | Custom compounded; non-standard formulations |
The bottom line
DSIP is a neuropeptide compound with research interest in sleep, stress, neuroendocrine. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying neuropeptide signaling and neural modulation
- • Individuals interested in sleep under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Selank
Anxiolytic peptide with complementary stress-reduction effects
Semax
Neuropeptide for cognitive enhancement and neuroprotection
Epitalon
Pineal peptide involved in melatonin and sleep regulation
BPC-157
Systemic protective peptide with neurotransmitter modulating effects
Frequently asked questions
References
- [1] Schneider-Helmert D, Schoenenberger GA.. Effects of DSIP in man: multifunctional psychophysiological properties besides induction of natural sleep. Neuropsychobiology (1983). doi: 10.1159/000118001 PMID: 6316199
- [2] Graf MV, Kastin AJ.. Delta sleep-inducing peptide (DSIP): a review. Neurosci Biobehav Rev (1984). doi: 10.1016/0149-7634(84)90022-6 PMID: 6095151
- [3] Kovalzon VM, Strekalova TV.. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem (2006). doi: 10.1111/j.1471-4159.2006.03693.x PMID: 16553621
- [4] Prudchenko IA, Starosciak BJ, Bhargava HN, Bhargava KP.. Delta sleep-inducing peptide: antinociceptive effects. Peptides (1995).
- [5] Khvatova EM, Samartzev VN, Zagoskin PP, et al.. Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia. Peptides (2003). doi: 10.1016/j.peptides.2003.06.001 PMID: 14612198